2013
DOI: 10.1016/j.gene.2013.02.022
|View full text |Cite
|
Sign up to set email alerts
|

Cell cycle arrest in Batten disease lymphoblast cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(3 citation statements)
references
References 37 publications
0
3
0
Order By: Relevance
“…However, chemokines have not been studied in great detail in a healthy brain or in Batten disease, and the extent to which they may play a part in neurodegeneration remains unclear. Additionally, females are more vulnerable than males to develop Alzheimer’s disease, and although androgens have been studied less extensively than estrogens, androgens exert anti-inflammatory effects on microglia in AD models [39, 40].…”
Section: Discussionmentioning
confidence: 99%
“…However, chemokines have not been studied in great detail in a healthy brain or in Batten disease, and the extent to which they may play a part in neurodegeneration remains unclear. Additionally, females are more vulnerable than males to develop Alzheimer’s disease, and although androgens have been studied less extensively than estrogens, androgens exert anti-inflammatory effects on microglia in AD models [39, 40].…”
Section: Discussionmentioning
confidence: 99%
“…8 Studies have linked the protein to intracellular trafficking, autophagy, apoptosis, lysosomal pH homeostasis, cell cycle control, osmoregulation, and calcium homeostasis. [9][10][11][12][13][14][15][16][17][18][19][20][21][22] However, the precise function of CLN3 is still not known. As a result, there are currently no effective treatments for the disease.…”
Section: Introductionmentioning
confidence: 99%
“…Acid sphingomyelinase-derived ceramide specifically binds to and activates CTSD [Heinrich at al., 1999]. Several reports have related impaired CLN3 expression to the accumulation of ceramide [Kang et al, 2013; Makoukji et al, 2015; Rusyn et al, 2008]. Rusyn et al reported that wild type CLN3, but not mutant CLN3, binds galactosylceramide, and suggested that CLN3 may function as a galactosylceramide transporter [Rusyn et al, 2008].…”
Section: Discussionmentioning
confidence: 99%